Profile of bevacizumab and its potential in the treatment of cervical cancer
about
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials.
P2860
Profile of bevacizumab and its potential in the treatment of cervical cancer
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Profile of bevacizumab and its potential in the treatment of cervical cancer
@ast
Profile of bevacizumab and its potential in the treatment of cervical cancer
@en
Profile of bevacizumab and its potential in the treatment of cervical cancer
@nl
type
label
Profile of bevacizumab and its potential in the treatment of cervical cancer
@ast
Profile of bevacizumab and its potential in the treatment of cervical cancer
@en
Profile of bevacizumab and its potential in the treatment of cervical cancer
@nl
prefLabel
Profile of bevacizumab and its potential in the treatment of cervical cancer
@ast
Profile of bevacizumab and its potential in the treatment of cervical cancer
@en
Profile of bevacizumab and its potential in the treatment of cervical cancer
@nl
P2860
P3181
P356
P1476
Profile of bevacizumab and its potential in the treatment of cervical cancer
@en
P2093
Christine M Fisher
Tracey E Schefter
P2860
P304
P3181
P356
10.2147/OTT.S73251
P407
P577
2015-01-01T00:00:00Z